Lilly announces the first cardiovascular indication for a dual GIP/GLP-1 agonist

The US Food and Drug Administration has approved Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes who are at high risk for those events ^[1]. Eli Lilly announced the decision on August 28, 2026, as the European Society of Cardiology's annual Congress opened in Munich ^[2].

Mounjaro was already approved alongside diet and exercise to improve blood sugar in adults and children 10 years and older with type 2 diabetes ^[1]. It is now the first and only dual GIP and GLP-1 receptor agonist with a cardiovascular risk-reduction claim ^[1][3]. Novo Nordisk's semaglutide products got there first: Wegovy was approved in March 2024 for adults with heart disease and overweight or obesity, and Ozempic is approved to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease ^[2]. Semaglutide activates the GLP-1 receptor alone ^[2].

What the trial showed

The approval rests on SURPASS-CVOT (NCT04255433), which Lilly describes as the first cardiovascular outcomes trial to test two incretin medicines head-to-head instead of against placebo ^[1][3]. The randomized, double-blind phase 3 trial enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease at 640 sites in 30 countries ^[1][3]. Participants were assigned 1:1 to tirzepatide (15 mg or the maximum tolerated dose) or dulaglutide (Trulicity) 1.5 mg, both injected once weekly ^[1][3].

Over a median follow-up of 210.1 weeks — about four years — a primary endpoint event occurred in 801 patients (12.2%) taking tirzepatide and 862 (13.1%) taking dulaglutide (hazard ratio 0.92; 95.3% confidence interval 0.83–1.01; P = .003 for non-inferiority; P = .09 for superiority) ^[3]. That works out to an 8% lower relative rate of MACE-3 with Mounjaro ^[1][2].

The wording matters. Tirzepatide met the bar for non-inferiority to dulaglutide, but superiority was not established ^[1][3]. Because the confidence interval crosses 1.00 and the superiority test did not reach statistical significance, the label reflects that Mounjaro performed as well as a drug already known to cut cardiovascular risk — not that it beat it ^[3]. "We set a higher bar by testing Mounjaro against a GLP-1 medicine with proven cardiovascular benefit," said Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health ^[1][2]. Pharmacy Times noted that pharmacists fielding questions framed around tirzepatide being "better for the heart" should anchor conversations in what the trial actually established ^[3].

Safety in the trial was generally consistent with tirzepatide's known profile. The most common side effects were gastrointestinal, generally mild to moderate, and clustered during the dose-escalation period ^[1][3]. Labeling continues to carry a boxed warning for thyroid C-cell tumors, plus warnings about pancreatitis, low blood sugar when combined with insulin or sulfonylureas, and dehydration that can lead to kidney problems ^[1][3].

Why it matters for patients

For people with type 2 diabetes and existing heart disease, the practical change is what the prescribing information now says a drug is proven to do. Insurers and prescribers often lean on labeled indications when deciding coverage and treatment sequencing, and Mounjaro now carries a formal cardiovascular claim rather than a glucose-and-weight claim alone ^[3].

The evidence does not say Mounjaro protects the heart better than a GLP-1 drug such as dulaglutide, semaglutide or others with established benefit ^[1][3]. A separate claims-based analysis published in The BMJ compared tirzepatide starters with sitagliptin and reported a lower one-year MACE risk (2.9% vs 4.4%; HR 0.68; number needed to treat 70), but the authors cautioned that the observational design cannot rule out residual confounding ^[3].

One limit to note: the approval covers adults with type 2 diabetes at high risk of these events ^[1]. The sources do not address whether tirzepatide's obesity brand, Zepbound, will get a similar claim, so that remains unknown.

What happens next

Data from SURPASS-CVOT has already been added to Mounjaro's product information in the European Union, and regulatory submissions based on the trial are under review in additional markets ^[1]. Full results were published in The New England Journal of Medicine ^[1][3]. Lilly has not said publicly when updated US labeling and patient materials will reach pharmacies.